Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

Are botanical drugs part of the future of medicine?

Botanical drugs are stepping into the space between traditional remedies and modern pharmaceuticals

Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

Navigating NHS Market Access: Policy Change and Opportunity in England

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

Petauri Evidence

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

FDA approves Apellis’ Empaveli for two rare kidney diseases

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US

- PMLiVE

Trust and trends – proactive protection

To thrive in today’s communication ecosystem, we must tailor our messaging rationally and emotionally

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

- PMLiVE

BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

- PMLiVE

Improving transparency and traceability within the supply chain’s first mile

How manufacturers can implement processes to help improve this critical part of the supply chain

- PMLiVE

Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

Treatment options following disease progression have previously been limited for many patients

- PMLiVE

FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

Phenylketonuria affects one in every 13,500 to 19,000 newborns in the US

- PMLiVE

Motivating low-performance teams

Why some teams act in the same way as organisms that are metabolically impaired

- PMLiVE

GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

The deal includes a PDE3/4 inhibitor in clinical development for COPD

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links